title: [THE INFLUENCE OF HYDROGEN SULFIDE ON COLLAGEN-INDUCED AGGREGATION OF HUMAN PLATELETS].
abstract: Study the impact of hydrogen sulfide on collagen-induced platelet aggregation from healthy donors and patients with type 2 diabetes. In healthy individuals, in contrast to patients with type 2 diabetes, NaHS significantly inhibited platelet aggregation. Activators of cAMP signaling (forskolin and phosphodiesterase inhibitor) significantly reduced platelet aggregation in both groups of examinees. NO-synthase inhibitors increased platelet aggregation in healthy volunteers, but not in patients with type 2 diabetes. The presence of H2S donor did not alter the extent of platelet aggregation at high concentrations of cAMP or decreased production of nitric oxide. It is assumed that the antiplatelet effect of H2S is not associated with the effect on the signal system, mediated cAMP or nitric oxide. Change H2S-dependent regulation of platelet aggregation in patients with type 2 diabetes is caused by disorders have been reported with this disease: the increase of intracellular calcium ion concentration, oxidative damage to proteins, hyperhomocysteinemia, glycosylation of key proteins involved in this process.
authors.forename: I V
authors.initials: IV
authors.lastname: Petrova
authors.forename: O A
authors.initials: OA
authors.lastname: Trubacheva
authors.forename: O S
authors.initials: OS
authors.lastname: Mangataeva
authors.forename: T E
authors.initials: TE
authors.lastname: Suslova
authors.forename: I V
authors.initials: IV
authors.lastname: Kovalev
authors.forename: S V
authors.initials: SV
authors.lastname: Gusakova
mesh_terms: D000328:Adult; D001792:Blood Platelets / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D002118:Calcium / Q000378:metabolism; D016022:Case-Control Studies; D005576:Colforsin / Q000494:pharmacology; D003094:Collagen / Q000378:metabolism* / Q000494:pharmacology; D000242:Cyclic AMP / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000378:metabolism* / Q000473:pathology; D005260:Female; D064426:Gasotransmitters / Q000494:pharmacology; D006031:Glycosylation / Q000187:drug effects; D006801:Humans; D006862:Hydrogen Sulfide / Q000494:pharmacology*; D008297:Male; D008875:Middle Aged; D009569:Nitric Oxide / Q000378:metabolism; D020030:Nitric Oxide Donors / Q000494:pharmacology; D052250:Nitric Oxide Synthase Type III / Q000378:metabolism; D010084:Oxidation-Reduction; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology; D010974:Platelet Aggregation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology; D061251:Primary Cell Culture; D050050:Protein Carbonylation / Q000187:drug effects; D013440:Sulfides / Q000737:chemistry / Q000494:pharmacology
chemical_list: D064426:Gasotransmitters; D020030:Nitric Oxide Donors; D010726:Phosphodiesterase Inhibitors; D010975:Platelet Aggregation Inhibitors; D013440:Sulfides; D005576:Colforsin; D009569:Nitric Oxide; D003094:Collagen; D000242:Cyclic AMP; C496314:NOS3 protein, human; D052250:Nitric Oxide Synthase Type III; C025451:sodium bisulfide; D002118:Calcium; D006862:Hydrogen Sulfide